May 15th 2008 - ERYtech Pharma, a French biotechnology company, announces the inclusion of its last patient in its Phase II clinical trial for relapsed Acute Lymphoblastic Leukaemia (ALL).The main goal of this trial is to evaluate the pharmacokinetic, the pharmacodynamic and the safety of GRASPA®, ERYtech Pharma’s new medicinal product. Twenty four patients, comprised of nine adults and nine children received at least one dose of. GRASPA® three other child, and three adult patients received the control product, the free form of native E. coli L-Asparaginase... ERYtech's Press Release -
